The Listing Got Headlines, But The 29% Q2 Revenue Growth Behind (Nasdaq: BSEM) Matters More

At 10:45AM EST Tuesday morning, management

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored The Listing Got Headlines, But The 29% Q2 Revenue Growth Behind (Nasdaq: BSEM) Matters More *Click Here To Get Our Alerts Faster Via SMS* August 20th Greetings Readers, At 10:45AM EST Tuesday morning, management at BioStem Technologies, Inc. (Nasdaq: BSEM) took the microphone at the Sidoti MicroCap Virtual Conference. Small event. Notable timing. It is this team's first turn in front of a dedicated small-cap audience since BSEM shares went live on the Nasdaq Capital Market on August 7th. BSEM Chairman and CEO Jason Matuszewski called the listing, "an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy." Five days later the company posted second quarter results. Net revenue reached $7.9Mn, up roughly 29% from $6.1Mn in the first quarter, with hospital revenue climbing to $6.7Mn from $5.4Mn and gross margin holding at 61%. Management then lifted the floor on its full-year outlook, moving the 2026 range to $26Mn to $29Mn from $25Mn to $29Mn. The intellectual property file has moved as well. Eight U.S. design patents covering fenestrated human placental allograft technologies were issued around the quarter, four of them announced July 8th as D1131805, D1130758, D1130759 and D1130760, inside a worldwide file the company describes as exceeding 100 patents and applications. About BioStem Technologies, Inc. (Nasdaq: BSEM) BioStem develops, manufactures and commercializes allograft products derived from perinatal tissue, the placental membranes donated after scheduled deliveries. Proprietary BioRetain®, CryoTek® and SteriTek® methods are built to preserve the structure and biology of that tissue. The commercial shelf runs under the Neox®, Clarix®, VENDAJE® and American Amnion™ brands, out of a Pompano Beach, Florida operation accredited by the American Association of Tissue Banks and run to current Good Tissue and Good Manufacturing Practices standards. Revenue arrives through two channels, hospitals and physician offices, and the hospital side is now the engine. It came by purchase. On January 21st, BSEM closed on BioTissue Holdings' surgical and wound care business: roughly $15Mn cash up front, up to $10Mn tied to a 510(k) clearance milestone, and up to $15Mn in commercial royalty milestones, a package trade press valued near $40Mn. The deal delivered the Neox and Clarix brands, a national sales force and the group purchasing contracts that unlock hospital systems, on lines that produced approximately $29Mn of 2025 sales. Barry Hassett, who ran that business at BioTissue, became Chief Commercial Officer. Sources: BSEM Website. BSEM Presentation. Behind The Scenes: The August 12th Call Listen to the second quarter call and the strategy gets plain. Matuszewski framed the period around plumbing rather than headlines, telling listeners the team had, "completed the implementation of BioStem's own customer relationship management system, and continued building the commercial organization needed to support our growth strategy." Hassett put numbers on the field. BSEM is tracking toward more than 40 W-2 representatives and more than 30 independent agents by year-end, from 30 direct reps and five regional directors at the time of the call. He sized the addressable surgical and wound care set near $26Bn, against inherited group purchasing agreements that already reach more than 70% of U.S. hospital beds. 7 Potential Catalysts Putting (Nasdaq: BSEM) On Our Watchlist Thursday #1. Public Float Sits Under 15Mn Shares (Volatility Potential Could Be Heightened). With approximately 14.03Mn shares in its float, BSEM reads as a low float idea, which means the potential for heightened volatility may be significant. #2. A Fresh Nasdaq Listing Widens The Audience. A move from the OTC Markets to the Nasdaq Capital Market occurred on August 7th, and BSEM now clears a listing standard many screens require before a name is even eligible for review. #3. Guidance Floor Raised After A 29% Sequential Quarter. Management lifted the low end of the 2026 revenue range to $26Mn on August 12th, and BSEM has already booked $14.0Mn across the first half. #4. Hospital Access Reaches Most Of America's Beds. Group purchasing agreements carried over from the BioTissue purchase cover more than 70% of U.S. hospital beds, a distribution footprint BSEM is only beginning to work. #5. A Margin Step Change Is Scheduled, Not Hypothetical. Management has a dated path to in-house manufacturing in 2027, and the BSEM finance chief framed that move as worth 15 to 20 percentage points of gross margin. #6. Two Clinical Readouts Land Inside Twelve Months. Top-line venous leg ulcer data is expected in the second half and a first 510(k)-cleared product is targeted for late this year, both of which put BSEM in front of new prescriber conversations. #7. Analyst Coverage With A $7 Target. H.C. Wainwright reinitiated coverage of BSEM back in May and currently maintains a $7.00 target, representing a meaningful potential upside from current levels. The Closing Read None of this makes (Nasdaq: BSEM) a finished story. A Nasdaq listing, audited 2024 and 2025 financials, a raised guidance floor and a hospital channel that grew for two straight quarters give market watchers something concrete to measure. Read the filings and let the next two quarters do the arguing. We're kicking-off coverage on BioStem Technologies, Inc. (Nasdaq: BSEM). Be on the lookout for updates coming your way soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/19/2026 and ending on 08/20/2026 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Sideways Frequency LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (BSEM:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/bsem-9laoy/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice